Aimee Doran

1.7k total citations
20 papers, 1.1k citations indexed

About

Aimee Doran is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Aimee Doran has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Cardiology and Cardiovascular Medicine and 5 papers in Surgery. Recurrent topics in Aimee Doran's work include Pulmonary Hypertension Research and Treatments (18 papers), Heart Failure Treatment and Management (5 papers) and Cardiovascular Issues in Pregnancy (5 papers). Aimee Doran is often cited by papers focused on Pulmonary Hypertension Research and Treatments (18 papers), Heart Failure Treatment and Management (5 papers) and Cardiovascular Issues in Pregnancy (5 papers). Aimee Doran collaborates with scholars based in United States and Switzerland. Aimee Doran's co-authors include D. Dunbar Ivy, Lori Claussen, Robyn J. Barst, Robert H. Friesen, Steven H. Abman, Anji T. Yetman, Brandie D. Wagner, Allison Widlitz, A. Morganti and Erika B. Rosenzweig and has published in prestigious journals such as Journal of the American College of Cardiology, CHEST Journal and The American Journal of Cardiology.

In The Last Decade

Aimee Doran

19 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aimee Doran United States 14 939 712 316 204 177 20 1.1k
Lars Bo Ilkjær Denmark 11 593 0.6× 551 0.8× 94 0.3× 200 1.0× 175 1.0× 31 861
Philip Marino United Kingdom 12 800 0.9× 455 0.6× 380 1.2× 217 1.1× 33 0.2× 25 1.0k
Pierre Wauthy Belgium 14 556 0.6× 510 0.7× 250 0.8× 218 1.1× 34 0.2× 36 812
Hamid Amoozgar Iran 14 217 0.2× 197 0.3× 228 0.7× 179 0.9× 78 0.4× 99 583
J.B. Seward United States 14 261 0.3× 732 1.0× 282 0.9× 254 1.2× 44 0.2× 32 983
Jeffrey S. Sager United States 10 294 0.3× 104 0.1× 50 0.2× 286 1.4× 31 0.2× 26 512
Laura Dos Spain 17 341 0.4× 744 1.0× 790 2.5× 431 2.1× 15 0.1× 60 1.1k
Clifford W. Barlow United Kingdom 16 240 0.3× 751 1.1× 322 1.0× 452 2.2× 9 0.1× 60 1.0k
Lars Idorn Denmark 15 252 0.3× 339 0.5× 487 1.5× 224 1.1× 14 0.1× 31 607
Alan S. Katz United States 11 231 0.2× 553 0.8× 159 0.5× 130 0.6× 17 0.1× 30 800

Countries citing papers authored by Aimee Doran

Since Specialization
Citations

This map shows the geographic impact of Aimee Doran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimee Doran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimee Doran more than expected).

Fields of papers citing papers by Aimee Doran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimee Doran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimee Doran. The network helps show where Aimee Doran may publish in the future.

Co-authorship network of co-authors of Aimee Doran

This figure shows the co-authorship network connecting the top 25 collaborators of Aimee Doran. A scholar is included among the top collaborators of Aimee Doran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimee Doran. Aimee Doran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shapiro, Shelley, et al.. (2013). Safety, Tolerability, and Efficacy of Overnight Switching From Sildenafil to Tadalafil in Patients With Pulmonary Arterial Hypertension. Cardiovascular Therapeutics. 31(5). 274–279. 12 indexed citations
2.
Takatsuki, Shinichi, et al.. (2012). Acute Pulmonary Vasodilator Testing With Inhaled Treprostinil in Children With Pulmonary Arterial Hypertension. Pediatric Cardiology. 34(4). 1006–1012. 15 indexed citations
3.
Rich, Jonathan D., et al.. (2011). The Effect of Diluent pH on Bloodstream Infection Rates in Patients Receiving IV Treprostinil for Pulmonary Arterial Hypertension. CHEST Journal. 141(1). 36–42. 47 indexed citations
4.
Zaccardelli, David, et al.. (2010). Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan. International Journal of Clinical Practice. 64(7). 885–891. 16 indexed citations
5.
Ivy, D. Dunbar, Brandie D. Wagner, Susan A. Dolan, et al.. (2009). Closed-Hub Systems with Protected Connections and the Reduction of Risk of Catheter-Related Bloodstream Infection in Pediatric Patients Receiving Intravenous Prostanoid Therapy for Pulmonary Hypertension. Infection Control and Hospital Epidemiology. 30(9). 823–829. 57 indexed citations
6.
Doran, Aimee, et al.. (2008). Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. International Journal of Clinical Practice. 62(160). 5–9. 87 indexed citations
7.
Ivy, D. Dunbar, Aimee Doran, K Smith, et al.. (2008). Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 51(2). 161–169. 138 indexed citations
8.
Doran, Aimee, et al.. (2008). Advances in Prostanoid Infusion Therapy for Pulmonary Arterial Hypertension. Journal of Infusion Nursing. 31(6). 336–345. 11 indexed citations
9.
Doran, Aimee, D. Dunbar Ivy, Robyn J. Barst, et al.. (2008). Guidelines for the Prevention of Central Venous Catheter-Related Bloodstream Infections with Prostanoid Therapy for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension. 7(1). 245–248. 7 indexed citations
10.
Wagner, Brandie D., et al.. (2008). Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension. CHEST Journal. 135(3). 745–751. 86 indexed citations
11.
Friesen, Robert H., et al.. (2007). Perioperative Complications in Children with Pulmonary Hypertension Undergoing Noncardiac Surgery or Cardiac Catheterization. Anesthesia & Analgesia. 104(3). 521–527. 145 indexed citations
12.
Ivy, D. Dunbar, Lori Claussen, & Aimee Doran. (2007). Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil. The American Journal of Cardiology. 99(5). 696–698. 64 indexed citations
13.
Rosenzweig, Erika B., Allison Widlitz, Aimee Doran, et al.. (2006). Reply. Journal of the American College of Cardiology. 47(9). 1915–1915. 1 indexed citations
14.
Rosenzweig, Erika B., D. Dunbar Ivy, Allison Widlitz, et al.. (2005). Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 46(4). 697–704. 191 indexed citations
15.
Ivy, D. Dunbar, Judith A. O’Connor, Michael R. Narkewicz, et al.. (2005). Portopulmonary Hypertension in Pediatric Patients. The Journal of Pediatrics. 147(1). 20–26. 47 indexed citations
16.
Yetman, Anji T., Amy L. Taylor, Aimee Doran, & D. Dunbar Ivy. (2005). Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. The American Journal of Cardiology. 95(5). 697–699. 38 indexed citations
17.
Ivy, D. Dunbar, et al.. (2004). Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. The American Journal of Cardiology. 93(7). 943–946. 63 indexed citations
18.
Narkewicz, M R, et al.. (2004). O0013 PORTOPULMONARY HYPERTENSION IN PEDIATRIC PATIENTS. Journal of Pediatric Gastroenterology and Nutrition. 39(Supplement 1). S11–S12.
19.
Ivy, D. Dunbar, et al.. (2003). Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. The American Journal of Cardiology. 92(7). 886–890. 33 indexed citations
20.
Barst, Robyn J., et al.. (2002). Pharmacokinetics and safety of bosentan, an oral dual endothelin receptor antagonist in children with pulmonary arterial hypertension BREATHE-3. 489. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lars Bo Ilkjær Breakdown of academic impact, for papers by Philip Marino Breakdown of academic impact, for papers by Pierre Wauthy Breakdown of academic impact, for papers by Hamid Amoozgar Breakdown of academic impact, for papers by J.B. Seward Breakdown of academic impact, for papers by Jeffrey S. Sager Breakdown of academic impact, for papers by Laura Dos Breakdown of academic impact, for papers by Clifford W. Barlow Breakdown of academic impact, for papers by Lars Idorn Breakdown of academic impact, for papers by Alan S. Katz
Rankless by CCL
2026